RU2010149618A - Новые производные оксазолидинона, способ их получения и применение - Google Patents
Новые производные оксазолидинона, способ их получения и применение Download PDFInfo
- Publication number
- RU2010149618A RU2010149618A RU2010149618/04A RU2010149618A RU2010149618A RU 2010149618 A RU2010149618 A RU 2010149618A RU 2010149618/04 A RU2010149618/04 A RU 2010149618/04A RU 2010149618 A RU2010149618 A RU 2010149618A RU 2010149618 A RU2010149618 A RU 2010149618A
- Authority
- RU
- Russia
- Prior art keywords
- acid
- oxazolidinone
- derivative
- methyl
- pyridin
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title claims abstract 34
- 238000000034 method Methods 0.000 title claims 7
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims abstract 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 10
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 239000001257 hydrogen Substances 0.000 claims abstract 10
- 239000010452 phosphate Substances 0.000 claims abstract 10
- -1 alkyl phosphate Chemical compound 0.000 claims abstract 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract 8
- 150000004712 monophosphates Chemical class 0.000 claims abstract 8
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims abstract 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract 6
- 150000002431 hydrogen Chemical class 0.000 claims abstract 6
- 229940024606 amino acid Drugs 0.000 claims abstract 5
- 235000001014 amino acid Nutrition 0.000 claims abstract 5
- 150000001413 amino acids Chemical class 0.000 claims abstract 5
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims abstract 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 4
- 229950006191 gluconic acid Drugs 0.000 claims abstract 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims abstract 3
- 239000002184 metal Chemical class 0.000 claims abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004471 Glycine Substances 0.000 claims abstract 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960000583 acetic acid Drugs 0.000 claims abstract 2
- 229960003767 alanine Drugs 0.000 claims abstract 2
- 235000004279 alanine Nutrition 0.000 claims abstract 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 235000003704 aspartic acid Nutrition 0.000 claims abstract 2
- 229940000635 beta-alanine Drugs 0.000 claims abstract 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical class OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims abstract 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract 2
- 229960004106 citric acid Drugs 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- 239000001530 fumaric acid Chemical class 0.000 claims abstract 2
- 229960002598 fumaric acid Drugs 0.000 claims abstract 2
- 239000000174 gluconic acid Chemical class 0.000 claims abstract 2
- 235000012208 gluconic acid Nutrition 0.000 claims abstract 2
- 235000013922 glutamic acid Nutrition 0.000 claims abstract 2
- 239000004220 glutamic acid Substances 0.000 claims abstract 2
- 229960002449 glycine Drugs 0.000 claims abstract 2
- 229960000310 isoleucine Drugs 0.000 claims abstract 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000468 ketone group Chemical group 0.000 claims abstract 2
- 239000004310 lactic acid Chemical class 0.000 claims abstract 2
- 229960000448 lactic acid Drugs 0.000 claims abstract 2
- 235000014655 lactic acid Nutrition 0.000 claims abstract 2
- 229960003136 leucine Drugs 0.000 claims abstract 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract 2
- 239000011976 maleic acid Chemical class 0.000 claims abstract 2
- 229940098895 maleic acid Drugs 0.000 claims abstract 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims abstract 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960005190 phenylalanine Drugs 0.000 claims abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960004838 phosphoric acid Drugs 0.000 claims abstract 2
- 229960002429 proline Drugs 0.000 claims abstract 2
- 229940032330 sulfuric acid Drugs 0.000 claims abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004474 valine Substances 0.000 claims abstract 2
- 229960004295 valine Drugs 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910001463 metal phosphate Chemical class 0.000 claims 5
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 241000192125 Firmicutes Species 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 241000194033 Enterococcus Species 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 241000606125 Bacteroides Species 0.000 claims 1
- JMUSXOANYBYNPO-CRIUFTBBSA-N CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC(CCN)=O)C)F Chemical compound CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC(CCN)=O)C)F JMUSXOANYBYNPO-CRIUFTBBSA-N 0.000 claims 1
- SFCWSXYLBCSIPW-MHJGDJFKSA-N CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC([C@@H](N)C(C)C)=O)C)F Chemical compound CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC([C@@H](N)C(C)C)=O)C)F SFCWSXYLBCSIPW-MHJGDJFKSA-N 0.000 claims 1
- MHGNXMXHWYNGQP-UXVCLIMPSA-N CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC([C@@H](N)C)=O)C)F Chemical compound CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC([C@@H](N)C)=O)C)F MHGNXMXHWYNGQP-UXVCLIMPSA-N 0.000 claims 1
- YMEULRBYEMLENZ-RNNSPPARSA-N CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC([C@H]1NCCC1)=O)C)F Chemical compound CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1[C@H](OC(C1)OC([C@H]1NCCC1)=O)C)F YMEULRBYEMLENZ-RNNSPPARSA-N 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- GAEJHMBHMYTUSX-NHVRPERQSA-N FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC(CCN)=O)=O)F Chemical compound FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC(CCN)=O)=O)F GAEJHMBHMYTUSX-NHVRPERQSA-N 0.000 claims 1
- BAQRLPIADPGITO-WKSPUGCPSA-N FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC([C@@H](N)C(C)C)=O)=O)F Chemical compound FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC([C@@H](N)C(C)C)=O)=O)F BAQRLPIADPGITO-WKSPUGCPSA-N 0.000 claims 1
- MJXSXNPKUKWXHU-ZOOGNTDASA-N FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC([C@@H](N)C)=O)=O)F Chemical compound FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC([C@@H](N)C)=O)=O)F MJXSXNPKUKWXHU-ZOOGNTDASA-N 0.000 claims 1
- WIIKFBIGCWQSKV-WKSPUGCPSA-N FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC([C@H]1NCCC1)=O)=O)F Chemical compound FC(C(=O)O)(F)F.CC=1OC(=NN1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(OC([C@H]1C)OC([C@H]1NCCC1)=O)=O)F WIIKFBIGCWQSKV-WKSPUGCPSA-N 0.000 claims 1
- UWWWHFDGRKQQCU-RSAXXLAASA-N FC(C(=O)O)(F)F.NCC(=O)OCC1=CC(=NO1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(O[C@H](C1)CCC(=O)N)=O)F Chemical compound FC(C(=O)O)(F)F.NCC(=O)OCC1=CC(=NO1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1C(O[C@H](C1)CCC(=O)N)=O)F UWWWHFDGRKQQCU-RSAXXLAASA-N 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- BYUWNQGABCUWIU-PFEQFJNWSA-N [(5r)-3-[3-fluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl 2-aminoacetate;hydrochloride Chemical compound Cl.O1C(C)=NN=C1C1=CC=C(C=2C(=CC(=CC=2)N2C(O[C@@H](COC(=O)CN)C2)=O)F)C=N1 BYUWNQGABCUWIU-PFEQFJNWSA-N 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 0 Cc1cc(N(C[C@](C*)C2)C2=O)cc(*)c1-c1cnc(C)cc1 Chemical compound Cc1cc(N(C[C@](C*)C2)C2=O)cc(*)c1-c1cnc(C)cc1 0.000 description 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Производные оксазолидинона формулы I или его фармацевтически приемлемая соль ! ! где R1 и соответственно обозначают водород или фтор; ! R2 обозначает -NR5R6, -OR7, фтор, алкилфосфат, монофосфат или соль фосфата; ! R5 и R6 независимо обозначают водород, С1-4алкил; ! R7 обозначает водород, С1-3алкил или ацилированную аминокислотную группу, где аминокислотой является аланин, глицин, пролин, изолейцин, лейцин, фенилаланин, β-аланин или валин; ! Het обозначает оксадиазолил, ! R3 обозначает водород, С1-4 алкильную группу, которая является незамещенной или замещенной циано, -(CH2)m-OR7 или кетогруппой, и ! m равен 0, 1, 2, 3 или 4. ! 2. Производные оксазолидинона по п.1, представляющие собой ! или ! ! 3. Производное оксазолидинона по п.1, где R1 обозначает водород и R1 обозначает фтор. ! 4. Производное оксазолидинона по п.1 или 2, где R2 обозначает -ОН. ! 5. Производное оксазолидинона по п.1, где R2 обозначает -OR7 и R7 обозначает ацилированную аминокислоту. ! 6. Производное оксазолидинона по п.1 или 2, где R2 выбран из группы, состоящей из монофосфата и металлической соли фосфата. ! 7. Производные оксазолидинона по п.1, где R3 обозначает метил. ! 8. Производное оксазолидинона по п.1, у которого фармацевтически приемлемая соль выбрана из группы, состоящей из солей соляной кислоты, бромноватой кислоты, серной кислоты, фосфорной кислоты, лимонной кислоты, уксусной кислоты, молочной кислоты, малеиновой кислоты, фумаровой кислоты, глюконовой кислоты, метансульфокислоты, гликоновой кислоты, янтарной кислоты, 4-толуолсульфокислоты, трифторуксусной кислоты, галутуро- новой кислоты, эмбоновой кислоты, глутаминовой кислоты и аспартовой кислоты. ! 9. Производное оксазолидинона по
Claims (32)
1. Производные оксазолидинона формулы I или его фармацевтически приемлемая соль
R2 обозначает -NR5R6, -OR7, фтор, алкилфосфат, монофосфат или соль фосфата;
R5 и R6 независимо обозначают водород, С1-4алкил;
R7 обозначает водород, С1-3алкил или ацилированную аминокислотную группу, где аминокислотой является аланин, глицин, пролин, изолейцин, лейцин, фенилаланин, β-аланин или валин;
Het обозначает оксадиазолил,
R3 обозначает водород, С1-4 алкильную группу, которая является незамещенной или замещенной циано, -(CH2)m-OR7 или кетогруппой, и
m равен 0, 1, 2, 3 или 4.
3. Производное оксазолидинона по п.1, где R1 обозначает водород и R1 обозначает фтор.
4. Производное оксазолидинона по п.1 или 2, где R2 обозначает -ОН.
5. Производное оксазолидинона по п.1, где R2 обозначает -OR7 и R7 обозначает ацилированную аминокислоту.
6. Производное оксазолидинона по п.1 или 2, где R2 выбран из группы, состоящей из монофосфата и металлической соли фосфата.
7. Производные оксазолидинона по п.1, где R3 обозначает метил.
8. Производное оксазолидинона по п.1, у которого фармацевтически приемлемая соль выбрана из группы, состоящей из солей соляной кислоты, бромноватой кислоты, серной кислоты, фосфорной кислоты, лимонной кислоты, уксусной кислоты, молочной кислоты, малеиновой кислоты, фумаровой кислоты, глюконовой кислоты, метансульфокислоты, гликоновой кислоты, янтарной кислоты, 4-толуолсульфокислоты, трифторуксусной кислоты, галутуро- новой кислоты, эмбоновой кислоты, глутаминовой кислоты и аспартовой кислоты.
9. Производное оксазолидинона по п.8, у которого фармацевтически приемлемая соль выбрана из солей соляной кислоты и трифторуксусной кислоты.
10. Производное оксазолидинона по п.1, выбранное из группы, включающей:
(S)-3-(4-(2-(5-глицилоксиметилизоксазол-3-ил)пиридин-5-ил)-3-фторфенил)-2-оксо-5-оксазолидинилметилацетамид трифторуксусной кислоты,
(R)-3-(4-(2-2-метил -[1,3,4] оксадиазол-5-ил) пиридин-5-ил)-3-фторфенил)- 5-([1,2,3] триазол-1-ил) метилоксазолидин-2-он,
(R)-3-(4-(2--2-метил-[1,3,4] оксадиазол-5-ил) пиридин-5-ил)-3-фторфенил)- 5-гидроксиметилоксазолидин-2-он,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил) пиридин-5-ил)-3-фтор-фенил)-5-глицилоксиметилоксазолидин-2-он-трифторуксусная кислота,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3,5-дифтор- фенил)-5-гидроксиметилоксазолидин-2-он,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-глицилоксиметилоксазолидин-2-она гидрохлорид,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(L-аланилокси) метилоксазолидин-2-он-трифторуксусная кислота,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(L-аланилокси) метилоксазолидин-2-она гидрохлорид,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(L-валилокси) метилоксазолидин-2-он-трифторуксусная кислота,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(L-валилокси) метилоксазолидин-2-она гидрохлорид,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(L-пролинилокси) метилоксазолидин-2-он-трифторуксусная кислота,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(L-пролинилокси) метилоксазолидин-2-она гидрохлорид,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(β-аланилокси) метилоксазолидин-2-он-трифторуксусная кислота,
(R)-3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пиридин-5-ил)-3-фторфенил)-5-(β-аланилокси) метилоксазолидин-2-она гидрохлорид,
(R)-[3-(4-(2-(2-метил-[1,3,4] оксадиазол-5-ил)пири-дин-5-ил)-3-фторфенил)-2-оксо-5-оксазолидинил] метилдинатрийфосфат.
21. Фармацевтическая композиция с антибактериальной активностью, содержащая производные оксазолидинона по любому из пп.1-20.
22. Соединение по любому из пп.1-20, применяемое для лечения бактериальной инфекции у субъекта.
23. Применение соединения по любому из пп.1-20 для изготовления композиции для лечения бактериальной инфекции у субъекта.
24. Применение по п.23, при котором бактериальная инфекция вызвана грамположительными бактериями.
25. Применение по п.24, при котором грамположительные бактерии выбраны из группы, включающей Staphylococcus, Enterococcus, Streptococcus, Bacteroides, Clostridium and Mycobacterium.
26. Применение по п.23, при котором грамположительные бактерии выбраны из группы, включающей Staphylococcus, Enterococcus и Streptococcus.
28. Способ по п.27, дополнительно включающий взаимодействие соединения формулы (V) с аминокислотой или фосфатом с получением соединения формулы (I).
29. Способ по п.28, дополнительно включающий взаимодействие соединения формулы (I) с кислотой для получения фармацевтически приемлемой соли.
30. Способ по п.27, дополнительно включающий взаимодействие соединения формулы (V), в котором R2 обозначает фосфат, с металлической солью с получением соединения формулы (V), у которого R2 обозначает металлическую соль фосфата.
32. Производное оксазолидинона, полученное способом по любому из пп.27-31.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030093342 | 2003-12-18 | ||
KR10-2003-0093342 | 2003-12-18 | ||
KR1020040058809A KR100854211B1 (ko) | 2003-12-18 | 2004-07-27 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
KR10-2004-0058809 | 2004-07-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006125761A Division RU2414469C3 (ru) | 2003-12-18 | 2004-12-17 | Новые производные оксазолидинона |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010149618A true RU2010149618A (ru) | 2012-06-27 |
RU2559620C2 RU2559620C2 (ru) | 2015-08-10 |
Family
ID=36660051
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010149618/04A RU2559620C2 (ru) | 2003-12-18 | 2004-12-17 | Новые производные оксазолидинона, способ их получения и применение |
RU2006125761A RU2414469C3 (ru) | 2003-12-18 | 2004-12-17 | Новые производные оксазолидинона |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006125761A RU2414469C3 (ru) | 2003-12-18 | 2004-12-17 | Новые производные оксазолидинона |
Country Status (24)
Country | Link |
---|---|
US (9) | US7816379B2 (ru) |
EP (2) | EP1699784B1 (ru) |
JP (1) | JP4739229B2 (ru) |
KR (1) | KR100854211B1 (ru) |
CN (4) | CN102516238B (ru) |
AT (1) | ATE514686T1 (ru) |
AU (2) | AU2004299413C1 (ru) |
BR (1) | BRPI0417800B8 (ru) |
CA (1) | CA2549062C (ru) |
CY (2) | CY1112445T1 (ru) |
DK (1) | DK1699784T3 (ru) |
ES (1) | ES2391820T3 (ru) |
HK (2) | HK1153738A1 (ru) |
HU (1) | HUS1500046I1 (ru) |
LT (1) | LTC1699784I2 (ru) |
LU (1) | LU92834I2 (ru) |
MX (2) | MXPA06006955A (ru) |
NL (1) | NL300759I1 (ru) |
NZ (2) | NZ547928A (ru) |
PL (1) | PL1699784T3 (ru) |
PT (1) | PT1699784E (ru) |
RU (2) | RU2559620C2 (ru) |
SI (1) | SI1699784T1 (ru) |
WO (1) | WO2005058886A1 (ru) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI454465B (zh) | 2003-06-03 | 2014-10-01 | Melinta Therapeutics Inc | 聯芳基雜環化合物及製法及其用途 |
US8324398B2 (en) | 2003-06-03 | 2012-12-04 | Rib-X Pharmaceuticals, Inc. | Process for the synthesis of biaryl oxazolidinones |
US7129259B2 (en) | 2003-12-17 | 2006-10-31 | Rib-X Pharmaceuticals, Inc. | Halogenated biaryl heterocyclic compounds and methods of making and using the same |
KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
MXPA06013540A (es) * | 2004-05-25 | 2007-01-26 | Astrazeneca Ab | Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas. |
EP1799677A1 (en) * | 2004-10-08 | 2007-06-27 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
US8399660B2 (en) | 2005-06-08 | 2013-03-19 | Rib-X Pharmaceuticals, Inc. | Process for the synthesis of triazoles |
CN100406455C (zh) * | 2006-02-20 | 2008-07-30 | 中国科学院上海药物研究所 | 含三氮唑基的噁唑烷酮类化合物及其制备方法和用途 |
KR101118402B1 (ko) * | 2006-11-10 | 2012-03-07 | 액테리온 파마슈티칼 리미티드 | 5-하이드록시메틸-옥사졸리딘-2-원 유도체 |
US8124623B2 (en) | 2006-11-10 | 2012-02-28 | Actelion Pharmaceuticals Ltd. | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials |
NZ589734A (en) * | 2008-05-09 | 2012-11-30 | Actelion Pharmaceuticals Ltd | 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases |
WO2010047737A2 (en) | 2008-09-02 | 2010-04-29 | Micurx Pharmaceuticals, Inc. | Antimicrobial indoline compounds for treatment of bacterial infections |
US8604209B2 (en) * | 2008-10-10 | 2013-12-10 | Trius Therapeutics, Inc. | Methods for preparing oxazolidinones and compositions containing them |
AU2009318783A1 (en) | 2008-11-20 | 2011-06-23 | Panacea Biotec Ltd. | Novel antimicrobials |
US8420668B2 (en) | 2008-11-28 | 2013-04-16 | Chugai Seiyaku Kabushiki Kaisha | 1-(2H)-isoquinolone derivative |
CN102439006A (zh) | 2009-02-03 | 2012-05-02 | 特留斯治疗学公司 | (r)-3-(4-(2-(2-甲基四唑-5-基)吡啶-5-基)-3-氟苯基)-5-羟甲基噁唑烷-2-酮二氢磷酸酯的晶型 |
CN101798302B (zh) | 2009-02-06 | 2014-11-05 | 上海盟科药业有限公司 | 抗生素类药物1-(邻-氟苯基)二氢吡啶酮的合成及生产的方法和工艺 |
ES2605472T3 (es) * | 2009-03-13 | 2017-03-14 | Sun Chemical B.V. | Compuesto de carbamato cíclico útil en composiciones curables con energía |
US8580767B2 (en) * | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
CA2765692A1 (en) | 2009-06-26 | 2010-12-29 | Panacea Biotec Ltd. | Novel azabicyclohexanes |
US20120208857A1 (en) * | 2009-10-13 | 2012-08-16 | Burak Eric S | Pharmaceutical Compositions |
IT1397023B1 (it) | 2009-11-27 | 2012-12-20 | Professional Dietetics Srl | Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva |
ES2368236B1 (es) * | 2009-12-23 | 2012-09-26 | Merck Sharp & Dohme Corp. | Agentes antibacterianos. |
CN102276595A (zh) * | 2010-04-16 | 2011-12-14 | 山东轩竹医药科技有限公司 | 含有五元杂环的噁唑烷酮抗菌素 |
KR101180174B1 (ko) | 2010-04-23 | 2012-09-05 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 |
US20120065170A1 (en) | 2010-09-10 | 2012-03-15 | Micurx Pharmaceuticals, Inc. | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections |
JP5902188B2 (ja) | 2010-11-01 | 2016-04-13 | メリンタ セラピューティクス,インコーポレイテッド | 薬学的組成物 |
JP6370550B2 (ja) | 2010-11-24 | 2018-08-08 | メリンタ・サブシディアリー・コーポレイション | 薬学的組成物 |
WO2012105574A1 (ja) * | 2011-01-31 | 2012-08-09 | 国立大学法人長崎大学 | 光学活性化合物又はその塩の製造方法 |
KR101653570B1 (ko) * | 2011-03-30 | 2016-09-02 | 주식회사 레고켐 바이오사이언스 | 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
EP2762479A4 (en) | 2011-09-29 | 2015-04-22 | Xuanzhu Pharma Co Ltd | OXAZOLIDINONE ANTIBACTERIAL MEDICINE BASED ON BIARYLIC HETEROCYCLE SUBSTITUTED |
WO2013059610A1 (en) | 2011-10-20 | 2013-04-25 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
CN103896963B (zh) * | 2012-12-26 | 2017-06-09 | 中国科学院上海药物研究所 | 苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 |
KR101480982B1 (ko) * | 2013-03-20 | 2015-02-03 | (주)셀인바이오 | 골형성 유도 화합물 및 이의 응용 |
CN104650142B (zh) * | 2013-11-25 | 2018-06-22 | 山东新时代药业有限公司 | 一种福沙匹坦二甲葡胺的制备方法 |
CA2939098A1 (en) | 2014-02-21 | 2015-08-27 | Micurx Pharmaceuticals, Inc. | Water-soluble o-carbonyl phosphoramidate prodrugs for therapeutic administration |
US10189870B2 (en) | 2014-04-18 | 2019-01-29 | Hangzhou Pushai Pharmaeutical Technology Co., Ltd. | Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof |
KR101597327B1 (ko) * | 2014-04-24 | 2016-02-24 | 동아에스티 주식회사 | 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제 |
WO2016009401A2 (en) * | 2014-07-18 | 2016-01-21 | Dr. Reddy's Laboratories Limited | Preparation of tedizolid phosphate |
CN104496979A (zh) * | 2014-09-17 | 2015-04-08 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
WO2016041505A1 (zh) * | 2014-09-17 | 2016-03-24 | 正大天晴药业集团股份有限公司 | 一种磷酸特地唑胺、其中间体以及它们的制备方法 |
CN105837633B (zh) * | 2015-01-12 | 2018-11-20 | 正大天晴药业集团股份有限公司 | 一种抗菌化合物的制备方法 |
CN105503955B (zh) * | 2014-10-15 | 2018-11-20 | 正大天晴药业集团股份有限公司 | 一种抗革兰氏阳性菌的化合物的制备方法 |
CN105566392B (zh) * | 2014-10-15 | 2018-12-21 | 正大天晴药业集团股份有限公司 | 一种细菌蛋白质合成抑制剂的制备方法 |
CN105418678B (zh) * | 2014-09-17 | 2018-11-20 | 正大天晴药业集团股份有限公司 | 一种磷酸特地唑胺的制备方法 |
CN104327119A (zh) * | 2014-10-17 | 2015-02-04 | 苏州明锐医药科技有限公司 | 磷酸泰地唑胺的制备方法 |
WO2016061772A1 (en) | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Nargenicin compounds and uses thereof as antibacterial agents |
WO2016088100A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
WO2016088103A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | A process for the preparation of tedizolid phosphate |
WO2016088101A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
CN104530128B (zh) * | 2014-12-30 | 2016-08-24 | 石药集团中诺药业(石家庄)有限公司 | 一种磷酸特地唑胺二钠盐及其制备方法 |
CN105859780A (zh) * | 2015-01-21 | 2016-08-17 | 山东康美乐医药科技有限公司 | 磷酸特地唑胺的制备方法 |
CN104558034A (zh) * | 2015-01-21 | 2015-04-29 | 齐鲁制药有限公司 | 磷酸特地唑胺二钠盐的新晶型及其制备方法 |
CN104610359B (zh) * | 2015-01-26 | 2017-07-14 | 成都新恒创药业有限公司 | 一种制备磷酸特地唑胺的关键中间体及其制备方法 |
CN105837634B (zh) * | 2015-01-30 | 2020-09-04 | 上海创诺制药有限公司 | 一种泰地唑胺磷酸酯结晶体及其制备方法 |
CN104592218B (zh) * | 2015-02-13 | 2015-11-04 | 江苏欧信医药化工有限公司 | 一种泰地唑胺的合成方法 |
CN110078764B (zh) * | 2015-04-10 | 2021-10-26 | 博瑞生物医药(苏州)股份有限公司 | 一种噁唑烷酮类化合物的制备方法 |
CN106146558A (zh) * | 2015-04-10 | 2016-11-23 | 博瑞生物医药(苏州)股份有限公司 | 新的噁唑烷酮类化合物及其制备方法 |
CN106279281B (zh) * | 2015-05-15 | 2018-08-03 | 重庆圣华曦药业股份有限公司 | 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法 |
CN106317114B (zh) * | 2015-07-02 | 2018-11-20 | 南京优科制药有限公司 | 一种磷酸特地唑胺的制备方法 |
CN106632298B (zh) * | 2015-11-03 | 2021-06-01 | 上海科胜药物研发有限公司 | 一种泰地唑胺的制备方法及其中间体 |
KR101855334B1 (ko) | 2015-12-11 | 2018-06-08 | 에스티팜 주식회사 | 옥사졸리디논 유도체의 중간체 제조방법 |
CN105496976A (zh) * | 2015-12-18 | 2016-04-20 | 北京万全德众医药生物技术有限公司 | 一种磷酸特地唑胺片及其制备方法 |
CN105949278B (zh) * | 2016-03-30 | 2019-12-06 | 南京曼杰生物科技有限公司 | 一种取代的四氢呋喃水溶性衍生物及其应用 |
CN106083994B (zh) * | 2016-04-18 | 2019-12-06 | 南京曼杰生物科技有限公司 | 取代的噁唑烷酮水溶性衍生物及其应用 |
WO2017181948A1 (zh) * | 2016-04-22 | 2017-10-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的恶唑烷酮化合物及其应用 |
CN107400126A (zh) * | 2016-05-19 | 2017-11-28 | 陕西合成药业股份有限公司 | 新型噁唑烷酮类化合物及其制备方法和在医学上的应用 |
CN106432182B (zh) * | 2016-09-06 | 2019-04-30 | 铜仁学院 | 特地唑胺中间体的合成方法 |
CN106632240A (zh) * | 2016-11-25 | 2017-05-10 | 山东轩德医药科技有限公司 | 一种2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法 |
US10087171B2 (en) | 2016-12-19 | 2018-10-02 | Actelion Pharmaceuticals Ltd | Crystalline forms of cadazolid |
CN107226825B (zh) * | 2017-06-14 | 2019-08-02 | 浙江海正药业股份有限公司 | 磷酸泰地唑胺铵盐及其晶型、制备方法和医药用途 |
EP3723758A4 (en) | 2017-12-13 | 2021-06-23 | Merck Sharp & Dohme Corp. | PHARMACEUTICAL COMPOSITIONS OF TEDIZOLID PHOSPHATE |
CN110804038B (zh) * | 2018-08-06 | 2021-03-05 | 上海博志研新药物技术有限公司 | 磷酸特地唑胺及其中间体的制备方法 |
EP3914587A4 (en) * | 2019-01-18 | 2022-11-23 | Merck Sharp & Dohme LLC | OXAZOLIDINONE COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS |
CN112940038A (zh) * | 2019-12-11 | 2021-06-11 | 华创合成制药股份有限公司 | 新型噁唑烷酮类化合物及其制备方法 |
CN111116551B (zh) * | 2020-01-03 | 2022-05-20 | 中国医科大学 | 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物 |
MX2022016063A (es) | 2020-06-18 | 2023-04-11 | Akagera Medicines Inc | Compuestos de oxazolidinona, composiciones de liposomas que comprenden compuestos de oxazolidinona y metodos de uso de los mismos. |
CN114315897B (zh) * | 2020-09-30 | 2024-05-17 | 北京澳合药物研究院有限公司 | 一种磷酸特地唑胺新晶体及其制备方法 |
CN112500433A (zh) * | 2020-12-23 | 2021-03-16 | 桂林南药股份有限公司 | 一种磷酸特地唑胺的制备方法 |
CN113197874B (zh) * | 2021-04-28 | 2023-05-26 | 北京福元医药股份有限公司 | 一种磷酸特地唑胺口服固体制剂 |
AR128071A1 (es) * | 2021-12-22 | 2024-03-20 | Akagera Medicines Inc | Composiciones liposomales de oxazolidinona |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU80081A1 (fr) | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4340606A (en) | 1980-10-23 | 1982-07-20 | E. I. Du Pont De Nemours And Company | 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents |
FR2500450A1 (fr) | 1981-02-25 | 1982-08-27 | Delalande Sa | Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique |
US4461773A (en) | 1982-09-15 | 1984-07-24 | E. I. Dupont De Nemours And Company | P-Oxooxazolidinylbenzene compounds as antibacterial agents |
EP0180507B1 (en) * | 1984-11-01 | 1990-05-16 | Motor Wheel Corporation | Styled wheel and apparatus for forming same |
CA1320730C (en) | 1987-10-16 | 1993-07-27 | The Du Pont Merck Pharmaceutical Company | Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
ATE146783T1 (de) | 1991-11-01 | 1997-01-15 | Upjohn Co | Substituierte aryl- und heteroaryl- phenyloxazolidinone |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
EP0673370B1 (en) * | 1992-12-08 | 1998-01-07 | PHARMACIA & UPJOHN COMPANY | Tropone-substituted phenyloxazolidinone antibacterial agents |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
NZ274966A (en) | 1993-11-22 | 1998-01-26 | Upjohn Co | Substituted-hydroxyacetyl piperazine phenyl oxazolidinone derivatives, use in pharmaceutical compositions |
UA52620C2 (ru) * | 1995-09-01 | 2003-01-15 | Фармація Енд Апджон Компані | Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами |
GB9702213D0 (en) | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
NZ502253A (en) | 1997-07-11 | 2001-06-29 | Upjohn Co | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone derivatives which are antibacterial agents |
EP1030852B1 (en) * | 1997-11-12 | 2003-09-17 | PHARMACIA & UPJOHN COMPANY | Oxazolidinone derivatives and pharmaceutical compositions |
PL344049A1 (en) * | 1998-05-18 | 2001-09-24 | Upjohn Co | Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
MXPA02012045A (es) * | 2000-06-05 | 2003-10-15 | Dong A Pharm Co Ltd | Nuevos derivados de oxazolidinona y proceso para su preparacion. |
KR100731469B1 (ko) * | 2000-06-05 | 2007-06-21 | 동아제약주식회사 | 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법 |
KR100713170B1 (ko) * | 2001-03-07 | 2007-05-02 | 동아제약주식회사 | 헤테로고리 또는 헤테로아로마틱 고리가 치환된 피리딘고리를 포함하는 옥사졸리디논 유도체 및 그의 제조방법 |
US20020115669A1 (en) | 2000-08-31 | 2002-08-22 | Wiedeman Paul E. | Oxazolidinone chemotherapeutic agents |
YU52403A (sh) | 2000-12-26 | 2006-03-03 | Dr.Reddy's Research Foundation | Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže |
EP1385844B1 (en) | 2001-04-07 | 2006-07-05 | Astrazeneca AB | Oxazolidinones containing a sulfonimid group as antibiotics |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
DK1427711T3 (da) * | 2001-09-11 | 2005-10-17 | Astrazeneca Ab | Oxazolidinon og/eller isoxazolinderivater som antibakterielle midler |
GB2396350A (en) | 2001-10-25 | 2004-06-23 | Astrazeneca Ab | Aryl substituted oxazolidinones with antibacterial activity |
NZ515881A (en) | 2001-12-03 | 2004-09-24 | New Zealand Dairy Board | Cheese flavour ingredient and method of its production |
AR038536A1 (es) * | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
MXPA04008273A (es) | 2002-02-28 | 2004-11-10 | Astrazeneca Ab | Derivados de oxazolidinona, procesos para su preparacion, y composiciones farmaceuticas que los contienen. |
PL372191A1 (en) * | 2002-02-28 | 2005-07-11 | Astrazeneca Ab | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents |
KR20050085193A (ko) | 2002-11-28 | 2005-08-29 | 아스트라제네카 아베 | 항균제로서의 옥사졸리디논 및(또는) 이속사졸린 유도체 |
WO2004048350A2 (en) | 2002-11-28 | 2004-06-10 | Astrazeneca Ab | Oxazolidinones as antibacterial agents |
GB0229518D0 (en) | 2002-12-19 | 2003-01-22 | Astrazeneca Ab | Chemical compounds |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
TW200500360A (en) | 2003-03-01 | 2005-01-01 | Astrazeneca Ab | Hydroxymethyl compounds |
GB0306358D0 (en) | 2003-03-20 | 2003-04-23 | Astrazeneca Ab | Chemical compounds |
RU2348628C2 (ru) * | 2003-07-02 | 2009-03-10 | Мерк Энд Ко., Инк. | Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные |
EP1654259A1 (en) * | 2003-07-02 | 2006-05-10 | Merck & Co., Inc. | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof |
WO2005051933A1 (en) | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby |
NZ529860A (en) | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
US7129259B2 (en) * | 2003-12-17 | 2006-10-31 | Rib-X Pharmaceuticals, Inc. | Halogenated biaryl heterocyclic compounds and methods of making and using the same |
KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
US20080064689A1 (en) | 2004-05-25 | 2008-03-13 | Astrazeneca Ab | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents |
CA2566963A1 (en) | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents |
MXPA06013540A (es) | 2004-05-25 | 2007-01-26 | Astrazeneca Ab | Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas. |
GB0411596D0 (en) | 2004-05-25 | 2004-06-30 | Astrazeneca Ab | Chemical process |
US20080021071A1 (en) | 2004-05-25 | 2008-01-24 | Astrazeneca Ab | 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents |
EP1799677A1 (en) | 2004-10-08 | 2007-06-27 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
US20090018123A1 (en) | 2005-06-20 | 2009-01-15 | Milind D Sindkhedkar | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation |
WO2007138381A2 (en) | 2005-10-14 | 2007-12-06 | Targanta Therapeutics Inc. | Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections |
EP2185549B1 (en) | 2007-08-06 | 2018-10-03 | Micurx Pharmaceuticals, Inc. | Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections |
US8604209B2 (en) | 2008-10-10 | 2013-12-10 | Trius Therapeutics, Inc. | Methods for preparing oxazolidinones and compositions containing them |
CN102439006A (zh) | 2009-02-03 | 2012-05-02 | 特留斯治疗学公司 | (r)-3-(4-(2-(2-甲基四唑-5-基)吡啶-5-基)-3-氟苯基)-5-羟甲基噁唑烷-2-酮二氢磷酸酯的晶型 |
US8580767B2 (en) | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
-
2004
- 2004-07-27 KR KR1020040058809A patent/KR100854211B1/ko active IP Right Grant
- 2004-12-17 PT PT04808458T patent/PT1699784E/pt unknown
- 2004-12-17 NZ NZ547928A patent/NZ547928A/en unknown
- 2004-12-17 MX MXPA06006955A patent/MXPA06006955A/es active IP Right Grant
- 2004-12-17 CN CN201110304983.4A patent/CN102516238B/zh not_active Ceased
- 2004-12-17 CN CN201210155386.4A patent/CN102702184B/zh not_active Ceased
- 2004-12-17 PL PL04808458T patent/PL1699784T3/pl unknown
- 2004-12-17 AU AU2004299413A patent/AU2004299413C1/en active Active
- 2004-12-17 EP EP04808458A patent/EP1699784B1/en active Active
- 2004-12-17 RU RU2010149618/04A patent/RU2559620C2/ru active
- 2004-12-17 CN CN2004800376122A patent/CN1894242B/zh not_active Ceased
- 2004-12-17 NZ NZ575842A patent/NZ575842A/en unknown
- 2004-12-17 BR BRPI0417800A patent/BRPI0417800B8/pt active IP Right Grant
- 2004-12-17 RU RU2006125761A patent/RU2414469C3/ru active Protection Beyond IP Right Term
- 2004-12-17 SI SI200431751T patent/SI1699784T1/sl unknown
- 2004-12-17 CA CA2549062A patent/CA2549062C/en active Active
- 2004-12-17 US US10/596,412 patent/US7816379B2/en active Active
- 2004-12-17 MX MX2012012028A patent/MX339597B/es unknown
- 2004-12-17 ES ES10183967T patent/ES2391820T3/es active Active
- 2004-12-17 DK DK04808458.6T patent/DK1699784T3/da active
- 2004-12-17 AT AT04808458T patent/ATE514686T1/de active
- 2004-12-17 EP EP10183967A patent/EP2305657B1/en active Active
- 2004-12-17 WO PCT/KR2004/003327 patent/WO2005058886A1/en active Application Filing
- 2004-12-17 CN CN2010105088241A patent/CN101982468B/zh not_active Ceased
- 2004-12-17 JP JP2006545238A patent/JP4739229B2/ja active Active
-
2008
- 2008-09-16 US US12/211,655 patent/US8420676B2/en active Active
-
2009
- 2009-02-17 AU AU2009200606A patent/AU2009200606B2/en active Active
-
2011
- 2011-07-27 HK HK11107829.9A patent/HK1153738A1/xx unknown
- 2011-09-27 HK HK11110172.6A patent/HK1155747A1/xx unknown
- 2011-09-28 CY CY20111100939T patent/CY1112445T1/el unknown
-
2013
- 2013-04-15 US US13/863,216 patent/US9163043B2/en active Active
-
2014
- 2014-08-13 US US14/459,161 patent/US20140350059A1/en not_active Abandoned
-
2015
- 2015-09-01 NL NL300759C patent/NL300759I1/nl unknown
- 2015-09-03 HU HUS1500046C patent/HUS1500046I1/hu unknown
- 2015-09-17 LU LU92834C patent/LU92834I2/xx unknown
- 2015-09-18 CY CY2015036C patent/CY2015036I2/el unknown
- 2015-09-22 LT LTPA2015032C patent/LTC1699784I2/lt unknown
-
2016
- 2016-08-30 US US15/251,049 patent/US20170049763A1/en active Pending
-
2017
- 2017-06-07 US US15/616,021 patent/US20170333414A1/en not_active Abandoned
-
2018
- 2018-08-03 US US16/054,538 patent/US20180344716A1/en not_active Abandoned
-
2019
- 2019-11-12 US US16/681,206 patent/US20200078345A1/en not_active Abandoned
-
2020
- 2020-06-08 US US16/895,816 patent/US20210121449A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010149618A (ru) | Новые производные оксазолидинона, способ их получения и применение | |
CA2196862A1 (en) | Substituted oxazolidinones | |
TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
TW200519088A (en) | Aryl or heteroaryl amide compounds | |
CZ34197A3 (en) | Heteroaryl-oxazolidinones, process of their preparation, their use and pharmaceutical composition containing thereof | |
EP1542696A1 (en) | Oxazolidinone derivatives as antimicrobials | |
CA2463544A1 (en) | Cross-linked glycopeptide-cephalosporin antibiotics | |
JP2012506908A5 (ru) | ||
JP6162704B2 (ja) | オキサゾリジノン誘導体のシラアナログ及びその合成 | |
MX2011005365A (es) | Antimicrobianos novedosos. | |
JP2010505904A (ja) | 抗菌薬としての3−(ベンゾ[d][1,3]ジオキソール−5−イルメチル)−4−(チオ)オキソ−2−(チオ)オキソ−アゾリジン−5−イリデン誘導体 | |
US20030232820A1 (en) | Method for synthesizing oxazinones | |
KR20080053209A (ko) | 신규한 옥사졸리디논 유도체, 이의 제조방법 및 이를함유하는 의약 조성물 | |
ES2368918T3 (es) | Nuevos derivados de oxazolidinona. | |
WO2009116090A2 (en) | Novel antimicrobials | |
TH84547B (th) | สารรักษาโรค |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant |